• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Down Over 200 Points; US Job Openings Rise In August

    10/3/23 12:20:53 PM ET
    $FEMY
    $LLY
    $OCEA
    $PNT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FEMY alert in real time by email

    U.S. stocks extended losses midway through trading, with the Nasdaq Composite falling more than 200 points on Tuesday.

    The Dow traded down 1.06% to 33,078.27 while the NASDAQ fell 1.60% to 13,094.83. The S&P 500 also fell, dropping, 1.27% to 4,233.76.

    Check This Out: Vivani Medical And 3 Other Stocks Under $2 Insiders Are Buying

     

    Leading and Lagging Sectors

    Materials shares fell by just 0.1% on Tuesday.

    In trading on Tuesday, consumer discretionary shares dipped by around 2%.

     

    Top Headline

    The number of job openings increased by 690,000 from the prior month to 9.61 million in August, compared to market estimates of 8.8 million.

     

    Equities Trading UP

    Vericity, Inc. (NASDAQ:VERY) shares shot up 87% to $11.06 after iA Financial Group announced it will acquire the company.

    Shares of POINT Biopharma Global Inc. (NASDAQ:PNT) got a boost, shooting 85% to $12.39. Eli Lilly And Co (NYSE:LLY) agreed to acquire POINT Biopharma Global at $12.50 per share in cash, an aggregate of approximately $1.4 billion.

    SciSparc Ltd. (NASDAQ:SPRC) shares were also up, gaining 33% to $4.8839 after the company announced it was granted a European patent for its core technology.

     

    Equities Trading DOWN

    SmileDirectClub, Inc. (NASDAQ:SDC) shares dropped 42% to $0.0932 after the company reported it received notice that its securities will be delisted from the Nasdaq.

    Shares of Ocean Biomedical, Inc. (NASDAQ:OCEA) were down 26% to $2.5850 as the company said its cancer-targeting immunotherapy antibody candidate demonstrated effective tumor reduction against an aggressive subset of Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor mutations.

    Femasys Inc. (NASDAQ:FEMY) was down, falling 36% to $2.4998 after gaining more than 30% on Monday.

    Also Check This Out: Wall Street's Most Accurate Analysts Say Hold These 3 Real Estate Stocks With Over 7% Dividend Yields

     

    Commodities

    In commodity news, oil traded up 1.5% to $90.13 while gold traded down 0.3% at $1,842.90.

    Silver traded up 0.4% to $21.51 on Tuesday while copper fell 0.3% to $3.6290.

     

    Euro zone

    European shares were lower today. The eurozone’s STOXX 600 fell 1.1% London’s FTSE 100 fell 0.54% while Spain’s IBEX 35 Index fell 1.65% The German DAX fell 1.06% French CAC 40 fell 1.01%, while Italy’s FTSE MIB Index fell 1.32%.

    French government budget deficit rose to EUR 187.9 billion in January to August 2023, compared to EUR 149.9 billion in the year-ago period.

     

    Asia Pacific Markets

    Asian markets closed lower on Tuesday, with Japan’s Nikkei 225 falling 1.64% and Hong Kong’s Hang Seng Index lost 2.69%. India’s S&P BSE Sensex, meanwhile, fell 0.5%.

    The S&P Global Indian manufacturing PMI fell to 57.5 in September from 58.6. The Reserve Bank of Australia maintained its cash rate at 4.1%. The value of new home loans for owner-occupied homes in Australia rose by 2.6% month-over-month to A$ 16.07 billion during August, while job advertisements slipped by 0.1% month-over-month in September.

     

    Economics

    The Logistics Manager’s Index rose to 52.4 in September.

    The IBD/TIPP Economic Optimism Index fell to 36.3 in October from September's reading of 43.2.

    The number of job openings increased by 690,000 from the prior month to 9.61 million in August.

    Now Read This: Top 2 Energy Stocks That Could Sink Your Portfolio This Quarter

     

    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 108,758,600 cases with around 1,177,280 deaths. India confirmed a total of at least 44,998,830 cases and 531,930 deaths, while France reported over 40,138,560 COVID-19 cases with 167,640 deaths. In total, there were at least 696,038,990 cases of COVID-19 worldwide with more than 6,921,810 deaths.

    Get the next $FEMY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FEMY
    $LLY
    $OCEA
    $PNT

    CompanyDatePrice TargetRatingAnalyst
    Eli Lilly and Company
    $LLY
    3/17/2026$850.00Hold → Reduce
    HSBC Securities
    Eli Lilly and Company
    $LLY
    2/25/2026$1250.00Outperform
    RBC Capital Mkts
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    Eli Lilly and Company
    $LLY
    1/7/2026$1250.00Buy
    UBS
    Eli Lilly and Company
    $LLY
    12/16/2025$1230.00Neutral → Buy
    Daiwa Securities
    Eli Lilly and Company
    $LLY
    12/15/2025$951.00 → $1145.00Buy
    Goldman
    Eli Lilly and Company
    $LLY
    12/15/2025$1286.00 → $1268.00Buy
    BofA Securities
    Femasys Inc.
    $FEMY
    11/20/2025$6.50Buy
    Laidlaw
    More analyst ratings

    $FEMY
    $LLY
    $OCEA
    $PNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

    Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi

    4/23/26 6:15:00 AM ET
    $LGVN
    $LLY
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026

    ATLANTA, April 22, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the commercial launch of FemaSeed Complete, a comprehensive fertility solution that enables OB/GYNs to perform first-line insemination entirely within their own practices. An estimated 10 million women in the United States experience infertility, yet fewer than half access care, and only a very small percentage ultimately undergo IVF. At the same time, U.S. fertility rates declined again in 2025 to a record low, underscoring the growing need for ear

    4/22/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies

    Kelonia's lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory multiple myeloma with clinical data recently highlighted in the 2025 ASH Annual Meeting plenary sessionAcquisition expands Lilly's genetic medicine capabilities with a novel in vivo gene delivery and integration technology that has potential for broad applicabilityINDIANAPOLIS and BOSTON, Mass., April 20, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Kelonia Therapeutics, Inc. ("Kelonia"), a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced a definitive agreement for Lilly to acquire Kelonia.Kelonia ha

    4/20/26 9:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FEMY
    $LLY
    $OCEA
    $PNT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 31, 2024 - FDA Roundup: May 31, 2024

    For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa

    5/31/24 3:22:42 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 7, 2024 - FDA Roundup: May 7, 2024

    For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ

    5/7/24 4:10:24 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 5, 2023 - FDA Roundup: December 5, 2023

    For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat

    12/5/23 5:00:21 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FEMY
    $LLY
    $OCEA
    $PNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Sulzberger Gabrielle

    4 - ELI LILLY & Co (0000059478) (Issuer)

    4/21/26 4:20:53 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Luciano Juan R

    4 - ELI LILLY & Co (0000059478) (Issuer)

    4/21/26 4:18:58 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Fyrwald J Erik

    4 - ELI LILLY & Co (0000059478) (Issuer)

    4/21/26 4:16:39 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FEMY
    $LLY
    $OCEA
    $PNT
    SEC Filings

    View All

    SEC Form DEF 14A filed by Femasys Inc.

    DEF 14A - FEMASYS INC (0001339005) (Filer)

    4/6/26 4:01:10 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - FEMASYS INC (0001339005) (Filer)

    4/1/26 9:13:11 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Femasys Inc.

    S-8 - FEMASYS INC (0001339005) (Filer)

    3/31/26 5:11:50 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    $LLY
    $OCEA
    $PNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Eli Lilly downgraded by HSBC Securities with a new price target

    HSBC Securities downgraded Eli Lilly from Hold to Reduce and set a new price target of $850.00

    3/17/26 7:55:56 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Eli Lilly with a new price target

    RBC Capital Mkts initiated coverage of Eli Lilly with a rating of Outperform and set a new price target of $1,250.00

    2/25/26 7:51:49 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Eli Lilly with a new price target

    Barclays initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $1,350.00

    2/20/26 8:24:27 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FEMY
    $LLY
    $OCEA
    $PNT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & CFO Montarce Lucas bought $494,627 worth of shares (715 units at $691.79), increasing direct ownership by 5% to 14,685 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/15/25 4:13:02 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Alvarez Ralph bought $500,473 worth of shares (758 units at $660.25) (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/14/25 4:12:51 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Pres., Lilly Oncology Van Naarden Jacob bought $647,360 worth of shares (1,000 units at $647.36), increasing direct ownership by 5% to 20,562 units (SEC Form 4)

    4 - ELI LILLY & Co (0000059478) (Issuer)

    8/13/25 4:15:45 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FEMY
    $LLY
    $OCEA
    $PNT
    Leadership Updates

    Live Leadership Updates

    View All

    Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth

    ATLANTA, April 01, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of John Canning as Chief Operating Officer. Mr. Canning is an accomplished medical device executive with more than 25 years of experience leading global operations and technology organizations within complex medical device companies. He brings a track record of scaling organizations, advancing product pipelines, and driving operational excellence across key functions to support commercial growth and product adoption. Prior to joining

    4/1/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

    ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide, announced today the appointment of Kenneth D. Eichenbaum, M.D., M.S.E., to its Board of Directors. Dr. Eichenbaum is a board-certified anesthesiologist with clinical affiliations at Corewell Health William Beaumont University Hospital and Trinity Health Oakland Hospital, bringing deep clinical expertise and strategic insight developed through more than 20 years of evaluating biotechnology and medical device companies and advising investment firms. He completed a fel

    3/18/26 9:00:00 AM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $FEMY
    $LLY
    $OCEA
    $PNT
    Financials

    Live finance-specific insights

    View All

    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

    Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi

    4/23/26 6:15:00 AM ET
    $LGVN
    $LLY
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lilly confirms date and conference call for first-quarter 2026 financial results announcement

    INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its first-quarter 2026 financial results on April 30, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.  The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  About LillyLilly is a medicine company turning science into heali

    4/16/26 10:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

    ATLANTA, March 31, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ:FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the year ended December 31, 2025 and provides a corporate update. Corporate Highlights from 4Q 2025 to date Initiated patient enrollment in the FINALE pivotal clinical trial evaluating FemBloc, advancing toward U.S. approval.Appointed Kenneth D. Eichenbaum, M.D., M.S.E., to the Board of Directors, strengthening leadership and strategic oversight.FemBloc permanent birth control system achieved certification under the Medical Device Single Au

    3/31/26 4:05:00 PM ET
    $FEMY
    Medical/Dental Instruments
    Health Care

    $FEMY
    $LLY
    $OCEA
    $PNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Eli Lilly and Company

    SC 13G/A - ELI LILLY & Co (0000059478) (Subject)

    10/23/24 5:17:34 PM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Vericity Inc.

    SC 13D/A - Vericity, Inc. (0001575434) (Subject)

    7/2/24 5:04:34 PM ET
    $VERY
    Life Insurance
    Finance

    SEC Form SC 13G filed by SciSparc Ltd.

    SC 13G - SciSparc Ltd. (0001611746) (Subject)

    3/6/24 5:02:18 PM ET
    $SPRC
    Biotechnology: Pharmaceutical Preparations
    Health Care